IntelGenx Grants Stock Options
SAINT LAURENT, QUEBEC–(Marketwire – Dec. 4, 2009) – IntelGenx Technologies Corp. (“IntelGenx”) (TSX VENTURE:IGX)(OTCBB:IGXT) voiced currently which the Company’s house of directors postulated options to take 125,000 usual shares in effect Nov 24, 2009. All options were postulated underneath the 2006 Stock Option Plan with an practice cost of C$0.65 and end in 5 years.
Of the sum batch options grant, 25,000 were postulated to any of the Company’s non worker directors Bernard Boudreau, Ian Troup and Bernd Melchers and vest immediately. The association additionally postulated 25,000 options to squeeze usual shares to any the CEO and President, Horst G. Zerbe and the CFO, Paul A. Simmons. The officer’s options vest over the duration of dual years at the rate of twenty-five % each 6 months.
About IntelGenx Corp.
IntelGenx Corp. is a drug smoothness association focused on the growth of verbal controlled-release products as good as novel fast decaying smoothness systems. The association uses the singular mixed covering smoothness complement to yield zero-order recover of active drug in the gastrointestinal tract. IntelGenx has additionally grown novel smoothness technologies for the fast smoothness of pharmaceutically active substances in the verbal form formed on the knowledge with fast decaying films. Intelgenx’s investigate and growth tube includes products for the diagnosis of pain, hypertension, osteoarthritis and depressive disorders. More report is accessible about the association at www.intelgenx.com.
The TSX Venture Exchange and OTC Bulletin Board have not reviewed and do not accept shortcoming for the endowment or correctness of this release.
